Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in ALK -positive ( ALK +) solid tumors in a histology-agnostic setting.

阿列克替尼 间变性淋巴瘤激酶 克里唑蒂尼 医学 碱性抑制剂 铈替尼 实体瘤疗效评价标准 肺癌 内科学 肿瘤科 癌症研究 临床试验 临床研究阶段 恶性胸腔积液
作者
Razelle Kurzrock,Amy R. MacKenzie,Adham Adel Jurdi,Basem Goueli,Walter Bordogna,Magalie Hilton,Erika Tavares Ferreira,Venice Rosalie Archer,Bettyna Brivet-Jones,Johannes Noé,Elizabeth Theogaraj,Lincoln W. Pasquina,Christine Marie Lovly
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): TPS3155-TPS3155 被引量:16
标识
DOI:10.1200/jco.2021.39.15_suppl.tps3155
摘要

TPS3155 Background: Anaplastic lymphoma kinase ( ALK) fusions are found in 3–8% of non-small cell lung cancers (NSCLC) and ̃0.2% of other tumor types. Alectinib is a selective, CNS-active ALK tyrosine kinase inhibitor approved as first-line treatment for adults with advanced ALK fusion-positive ( ALK-fp) NSCLC based on the phase 3 ALEX trial (NCT02075840; PMID 28586279). Preliminary evidence supports investigation of alectinib in a tumor-agnostic setting. ALK inhibitors have shown efficacy in ALK-fp tumor types other than NSCLC (PMIDs 29685646; 28977547; 30591488), with alectinib showing efficacy irrespective of ALK fusion partner and against ALK-activating mutations (PMIDs 29642598; 29559559). Methods: Alpha-T is a phase 2 open-label, single-arm trial (NCT04644315) with an innovative home-based remote design, currently enrolling adults with histologically confirmed, locally advanced/metastatic solid tumors (except lung cancer and cancers of unknown primary) harboring ALK fusions or selected mutations ( ALK-mut; R1275Q, F1245C, F1174X). The decentralized design permits enrollment regardless of location, allows most assessments to be home-based and maintains the relationship between patients (pts) and their treating oncologist. Key inclusion criteria: no alternative or unsuitable to receive standard therapy; ECOG PS 0–2; adequate hematologic, renal and hepatic functions; no prior ALK inhibitor; measurable solid tumor (RECIST 1.1) or primary brain tumor (RANO); asymptomatic or stable CNS metastases permitted. Pts are identified via the Foundation Medicine Inc. (FMI) Precision Enrollment service. For any solid tumor identified as ALK+ (fusion/selected mutation) by next-generation sequencing in tissue/blood (F1 CDx/F1L CDx, FMI), the ordering oncologist is given trial details and can liaise with a Science 37 investigator. Pts receive 600mg oral alectinib twice a day with food until radiological PD, unacceptable toxicity, withdrawal of consent or death. Home-based assessments (eg, physical examination, blood sampling, questionnaire completion) are conducted in-person by a mobile nurse at baseline and every 4 weeks, with remote support from the Science 37 investigator via their telemedicine platform. Tumor assessments at screening and every 8 weeks are performed at a local radiology facility. Primary endpoint: confirmed ORR by investigator in pts with ALK-fp tumors (RECIST 1.1). Secondary endpoints: ORR by independent review facility (IRF); DoR and PFS; intracranial ORR and DoR (IRF); OS and safety. Descriptive analyses are planned for pts with ALK-mut tumors and primary brain tumors. Pharmacokinetics and biomarkers will be evaluated. Patient-reported outcomes will be assessed via the EORTC QLQ-C30 and EuroQoL EQ-5D-5L questionnaires. Target enrollment is 50 pts with ALK-fp tumors evaluable by RECIST. As of 9 Feb 2021, 1 pt is in screening. Clinical trial information: NCT04644315.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
CipherSage的应助被xx采纳,获得10
2秒前
3秒前
郭同学完成签到,获得积分10
3秒前
3秒前
3秒前
3秒前
爱学习的小霸完成签到,获得积分10
4秒前
6秒前
张可爱完成签到,获得积分10
6秒前
7秒前
QJT发布了新的文献求助10
7秒前
arT发布了新的文献求助10
8秒前
gglh完成签到,获得积分10
9秒前
kuku发布了新的文献求助10
10秒前
黄毛虎发布了新的文献求助10
11秒前
执着新竹发布了新的文献求助10
11秒前
CodeCraft的应助被锂离子采纳,获得10
12秒前
科研66666发布了新的文献求助10
12秒前
未白发布了新的文献求助80
15秒前
15秒前
ahhh完成签到,获得积分10
18秒前
打打的应助被漂亮冰薇采纳,获得10
20秒前
果子大完成签到,获得积分10
20秒前
木子完成签到,获得积分10
21秒前
YDYD完成签到 ,获得积分10
21秒前
21秒前
21秒前
李李鱼完成签到 ,获得积分10
22秒前
22秒前
arT完成签到,获得积分10
22秒前
25秒前
果子大发布了新的文献求助10
26秒前
黄毛虎发布了新的文献求助10
27秒前
小升初发布了新的文献求助10
28秒前
小二郎的应助被zzz采纳,获得10
29秒前
Sidney完成签到 ,获得积分10
29秒前
30秒前
酷炫小甜瓜完成签到 ,获得积分10
30秒前
学阿斗完成签到,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186819
求助须知:如何正确求助?哪些是违规求助? 9575195
关于积分的说明 21839872
捐赠科研通 7784526
什么是DOI,文献DOI怎么找? 3434849
关于科研通互助平台的介绍 2559266
邀请新用户注册赠送积分活动 2481716